Jason A Somarelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7904271/publications.pdf

Version: 2024-02-01

331670 254184 2,458 73 21 43 h-index citations g-index papers 90 90 90 3830 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	<scp>EMT</scp> and <scp>MET</scp> : necessary or permissive for metastasis?. Molecular Oncology, 2017, 11, 755-769.	4.6	319
2	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of Clinical Oncology, 2019, 37, 1120-1129.	1.6	267
3	Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas., 2019, 194, 161-184.		244
4	Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. Cancer Research, 2017, 77, 6415-6428.	0.9	206
5	Plastic pollution solutions: emerging technologies to prevent and collect marine plastic pollution. Environment International, 2020, 144, 106067.	10.0	200
6	Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2. Molecular and Cellular Biology, 2016, 36, 2503-2513.	2.3	88
7	Cellular Migration and Invasion Uncoupled: Increased Migration Is Not an Inexorable Consequence of Epithelial-to-Mesenchymal Transition. Molecular and Cellular Biology, 2014, 34, 3486-3499.	2.3	80
8	Alternative splicing in multiple sclerosis and other autoimmune diseases. RNA Biology, 2010, 7, 462-473.	3.1	66
9	Epithelial/mesenchymal plasticity: how have quantitative mathematical models helped improve our understanding?. Molecular Oncology, 2017, 11, 739-754.	4.6	64
10	The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer and Metastasis Reviews, 2014, 33, 441-468.	5.9	59
11	Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2017, 23, 1346-1357.	7.0	58
12	Soft Tissue Sarcoma of the Extremities: What Is the Value of Treating at High-volume Centers?. Clinical Orthopaedics and Related Research, 2019, 477, 718-727.	1.5	46
13	Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. Oncotarget, 2016, 7, 50507-50521.	1.8	44
14	Molecular Biology and Evolution of Cancer: From Discovery to Action. Molecular Biology and Evolution, 2020, 37, 320-326.	8.9	43
15	Limb salvage versus amputation in patients with osteosarcoma of the extremities: an update in the modern era using the National Cancer Database. BMC Cancer, 2020, 20, 995.	2.6	43
16	E-Cadherin Represses Anchorage-Independent Growth in Sarcomas through Both Signaling and Mechanical Mechanisms. Molecular Cancer Research, 2019, 17, 1391-1402.	3.4	35
17	Bioengineering a Future Free of Marine Plastic Waste. Frontiers in Marine Science, 2019, 6, .	2.5	33
18	Evolution of the 12 kDa FK506-binding protein gene. Biology of the Cell, 2007, 99, 311-321.	2.0	31

#	Article	IF	CITATIONS
19	Molecular determinants for enzalutamide-induced transcription in prostate cancer. Nucleic Acids Research, 2019, 47, 10104-10114.	14.5	27
20	Fluorescence-based alternative splicing reporters for the study of epithelial plasticity in vivo. Rna, 2013, 19, 116-127.	3.5	25
21	Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. Biomarker Research, 2021, 9, 14.	6.8	24
22	The Hallmarks of Cancer as Ecologically Driven Phenotypes. Frontiers in Ecology and Evolution, 2021, 9, .	2.2	24
23	PhyloOncology: Understanding cancer through phylogenetic analysis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1867, 101-108.	7.4	22
24	Exploring the Diversity of the Marine Environment for New Anti-cancer Compounds. Frontiers in Marine Science, 2021, 7, .	2.5	22
25	Carcinosarcomas: tumors in transition?. Histology and Histopathology, 2015, 30, 673-87.	0.7	21
26	KLF4 Induces Mesenchymal–Epithelial Transition (MET) by Suppressing Multiple EMT-Inducing Transcription Factors. Cancers, 2021, 13, 5135.	3.7	21
27	Spliceosomal immunophilins. FEBS Letters, 2008, 582, 2345-2351.	2.8	20
28	To what extent did Neanderthals and modern humans interact?. Biological Reviews, 2009, 84, 245-257.	10.4	20
29	Improving Cancer Drug Discovery by Studying Cancer across the Tree of Life. Molecular Biology and Evolution, 2020, 37, 11-17.	8.9	20
30	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. Genes Chromosomes and Cancer, 2020, 59, 225-239.	2.8	18
31	From the Clinic to the Bench and Back Again in One Dog Year: How a Cross-Species Pipeline to Identify New Treatments for Sarcoma Illuminates the Path Forward in Precision Medicine. Frontiers in Oncology, 2020, 10, 117.	2.8	18
32	Analysis of immune subtypes across the epithelial-mesenchymal plasticity spectrum. Computational and Structural Biotechnology Journal, 2021, 19, 3842-3851.	4.1	18
33	An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance. Journal of Clinical Medicine, 2019, 8, 205.	2.4	17
34	A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. Molecular Cancer Therapeutics, 2020, 19, 2516-2527.	4.1	17
35	Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) Shows Efficacy Against Osteosarcoma. Molecular Cancer Therapeutics, 2020, 19, 1448-1461.	4.1	17
36	Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. PLoS ONE, 2019, 14, e0216934.	2.5	14

#	Article	IF	CITATIONS
37	Immune dysregulation and osteosarcoma: Staphylococcus aureus downregulates TGFâ $\hat{\mathfrak{el}}^2$ and heightens the inflammatory signature in human and canine macrophages suppressed by osteosarcoma. Veterinary and Comparative Oncology, 2020, 18, 64-75.	1.8	14
38	Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer. BMC Cancer, 2020, 20, 592.	2.6	14
39	A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 762-769.	3.9	13
40	A Comparative Oncology Drug Discovery Pipeline to Identify and Validate New Treatments for Osteosarcoma. Cancers, 2020, 12, 3335.	3.7	11
41	Baby Genomics: Tracing the Evolutionary Changes That Gave Rise to Placentation. Genome Biology and Evolution, 2020, 12, 35-47.	2.5	11
42	The somatic molecular evolution of cancer: Mutation, selection, and epistasis. Progress in Biophysics and Molecular Biology, 2021, 165, 56-65.	2.9	11
43	The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E) Journal of Clinical Oncology, 2018, 36, 5004-5004.	1.6	8
44	U1 small nuclear RNA variants differentially form ribonucleoprotein particles in vitro. Gene, 2014, 540, 11-15.	2.2	7
45	Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomes. , 2022, 39, .		7
46	The Marquesans at the fringes of the Austronesian expansion. European Journal of Human Genetics, 2019, 27, 801-810.	2.8	6
47	A Zebrafish Model of Metastatic Colonization Pinpoints Cellular Mechanisms of Circulating Tumor Cell Extravasation. Frontiers in Oncology, 2021, 11, 641187.	2.8	6
48	Identifying Modifiable and Non-modifiable Risk Factors of Readmission and Short-Term Mortality in Osteosarcoma: A National Cancer Database Study. Annals of Surgical Oncology, 2021, 28, 7961-7972.	1.5	5
49	An integrated comparative physiology and molecular approach pinpoints mediators of breath-hold capacity in dolphins. Evolution, Medicine and Public Health, 2021, 9, 420-430.	2.5	5
50	Extent of tumor fibrosis/hyalinization and infarction following neoadjuvant radiation therapy is associated with improved survival in patients with softâ€tissue sarcoma. Cancer Medicine, 2022, 11, 194-206.	2.8	5
51	Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells. Journal of Visualized Experiments, 2017, , .	0.3	4
52	Small nuclear RNA variants of three Bombyx mori strains. Entomological Research, 2008, 38, 61-68.	1.1	3
53	U2 snRNA variants are differentially incorporated into spliceosomes. Entomological Research, 2009, 39, 135-145.	1.1	3
54	Phenotypic plasticity and lineage switching in prostate cancer. , 2020, , 591-615.		3

#	Article	IF	CITATIONS
55	Treatment of Chondroblastoma with Denosumab. JBJS Case Connector, 2021, 11, .	0.3	3
56	A threeâ€dimensional model of the U1 small nuclear ribonucleoprotein particle. Entomological Research, 2010, 40, 104-112.	1.1	2
57	Identifying Modifiable and Non-modifiable Risk Factors of Readmission and Short-Term Mortality in Chondrosarcoma: A National Cancer Database Study. Annals of Surgical Oncology, 2022, 29, 1392-1408.	1.5	2
58	Manganese Porphyrin and Radiotherapy Improves Local Tumor Response and Overall Survival in Orthotopic Murine Mammary Carcinoma Models. Radiation Research, 2020, 195, 128-139.	1.5	2
59	Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry. Prostate Cancer and Prostatic Diseases, 2022, 25, 513-523.	3.9	2
60	Genomeâ€based identification of spliceosomal proteins in the silk moth ⟨i⟩Bombyx mori⟨li⟩. Archives of Insect Biochemistry and Physiology, 2010, 75, 231-263.	1.5	1
61	ASO Visual Abstract: Identifying Modifiable and Non-Modifiable Risk Factors of Readmission and Short-Term Mortality in Osteosarcoma—A National Cancer Database Study. Annals of Surgical Oncology, 2021, 28, 449-450.	1.5	1
62	ASO Author Reflections: Identifying Modifiable and Non-Modifiable Risk Factors of Readmission and Short-Term Mortality in Chondrosarcoma. Annals of Surgical Oncology, 2022, 29, 1409-1410.	1.5	1
63	Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223 Journal of Clinical Oncology, 2018, 36, 160-160.	1.6	1
64	ASO Visual Abstract: Identifying Modifiable and Non-Modifiable Risk Factors of Readmission and Short-Term Mortality in Chondrosarcoma: A National Cancer Database Study. Annals of Surgical Oncology, 2021, , 1.	1.5	1
65	Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide Journal of Clinical Oncology, 2020, 38, 183-183.	1.6	1
66	Post-Austronesian migrational wave of West Polynesians to Micronesia. Gene, 2022, 823, 146357.	2.2	1
67	Abstract SS02-02: A long walk from FGFR2 alternative splicing to cancer progression. , 2014, , .		0
68	A precision medicine strategy to identify the FGFR pathway as a novel target in colorectal cancer liver metastasis Journal of Clinical Oncology, 2018, 36, 660-660.	1.6	0
69	Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223 Journal of Clinical Oncology, 2018, 36, 5029-5029.	1.6	0
70	Abstract B038: Convergent hormone therapy resistance mediated by stress/dormancy-like pathways in prostate cancer., 2018,,.		0
71	A precision medicine drug discovery pipeline to identify dual CDK2/9 inhibition as a novel treatment for colorectal cancer Journal of Clinical Oncology, 2020, 38, e16056-e16056.	1.6	0
72	Abstract A114: Characterization of a metastatic prostate cancer xenograft derived from a patient of African ancestry. , 2020, , .		0

ARTICLE IF CITATIONS

Abstract P204: Targeting the p300/CBP epigenetic pathway to overcome hormone therapy resistance in advanced prostate cancer., 2021, , .